CSIMarket Company Name, Ticker, Customers, else..
Compass Pathways Plc  (NASDAQ: CMPS)
Other Ticker:  
 


 

Compass Pathways Plc

CMPS's Financial Statements and Analysis



Compass Pathways Plc increased third quarter of 2025 net loss per share of $-1.44 compare to net loss per share of $-0.56 recorded in the same quarter a year ago a decrease compare to $-0.41 realized in previous quarter.


third quarter of 2025
Earnings Per Share Revenues
$ -1.44 $  0 Mill
$-0.88     Unch.    



Compass Pathways Plc's Revenue fell by 0 % in third quarter of 2025 (Sep 30 2025) year on year, to $0 million and declined by sequentially.


Compass Pathways Plc is

More on CMPS's Income Statement



Compass Pathways Plc in the third quarter of 2025 recorded net loss of $-137.717 million, an increase from net loss of $-38.502 million in III. Quarter a year ago.

Sequentially net loss advanced

More on CMPS's Growth

Compass Pathways Plc Inventories
In Sep 30 2025 company's net cash and cash equivalents decreased by $-36 million


Compass Pathways Plc does not pay out common stock dividend.

In trailing twelve-month period Compass Pathways Plc payed $ -1.69 cash per share, on a free-cash flow basis .

Book value fell by -77.36 % sequentially to $0.39 per share, -52.14% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.39 per share from $ 1.74.

Company issued 2.00 million shares or 2.14 % in Sep 30 2025.


• More on CMPS's Dividends

 Market Capitalization (Millions) 496
 Shares Outstanding (Millions) 95
 Total Debt (Millions $) 31
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -237
 Cash Flow (TTM) (Millions $) -21
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 76




Compass Pathways Plc does not pay out common stock dividend.

In trailing twelve-month period Compass Pathways Plc had negative $ -1.69 cash flow per share, on a free-cash flow basis .

Book value fell by -77.36 % sequentially to $0.39 per share, -52.14% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.39 per share from $ 1.74.

Company issued 2.00 million shares or 2.14 % in Sep 30 2025.


• More on CMPS's Balance Sheets

 Market Capitalization (Millions) 496
 Shares Outstanding (Millions) 95
 Total Debt (Millions $) 31
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -237
 Cash Flow (TTM) (Millions $) -21
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 76
   


  News about Compass Pathways Plc Earnings

Compass Pathways Plc Unveils Impressive Third Quarter 2024 Performance Results

Analyzing the Third Quarter Dilemma: Compass Pathways Plc?s Financial StrugglesIn the ever-evolving landscape of the pharmaceutical industry, major players often dominate the headlines, overshadowing smaller entities that are striving to carve out their niche. One such overlooked entity is Compass Pathways Plc (CMPS), whose recent financial disclosures for the third quarter of 2024 reveal a profound operating deficit and raise questions about the company?s future trajectory. The Numbers: A Closer LookFor Q3 2024, Compass Pathways announced an operating deficit of $47.896 million. This marks a significant increase from a deficit of $34.062 million reported in the same quarter of the previous year. Coupled wi...

CMPS Shatters Expectations with First Quarter 2024 Financial Results

This positive top-line study is a sig...

Compass Pathways Plc Reports Impressive Fourth Quarter Efforts Amidst Industry Growth

Compass Pathways Plc, a biotechnology company focused on mental health innovation, has experienced significant growth in its share price over the past year. According to recent financial results, the company's shares have risen by 24.72% compared to a year ago, reaching an impressive 69.55% increase in the past 90 days alone. This positive trend is further supported by the fact that Compass Pathways Plc shares are currently trading on the NASDAQ at a significant 22.4% above its 52-week average.
One factor that could potentially contribute to this growth is the company's collaboration with Hackensack Meridian Health (HMH) to optimize the clinical model for COMP360 psilocybin treatment, a psychedelic subst...

Compass Pathways Plc Faces Growing Financial Concerns as Operating Shortfall Widens in Q3 2023



Compass Pathways Plc, a major player in the pharmaceutical preparations sector, recently announced its financial results for the third quarter of 2023. The company reported a significant operating shortfall of $-34.062 million, adding to concerns about its financial health. While the revenue figures are still undisclosed, analysis of the company's performance in the third quarter of 2022 reveals a similar trend. With shares declining and a net deficit increasing, it is imperative to explore the potential impact of these financial results on Compass Pathways Plc's future.
Operating Shortfall and Net Deficit:
The operating shortfall reported by Compass Pathways Plc for the third quarter of 20...

Compass Pathways Plc Suffers Shocking Financial Loss in Q2 2023: An Expert Analysis on Rising Costs and Unexplored Revenues



The second quarter financial results of major pharmaceutical preparations sector player, Compass Pathways Plc, have attracted the attention of industry researchers. Despite exhibiting an operating loss of $-32.664 million for the reporting period of April to June 2023, the company has not reported any revenue yet. This article aims to provide an overview of the company's financial performance and shed light on the market's expectations for revenue generation. Additionally, we will contextualize these results by considering the recent performance of Compass Pathways Plc stock.
Financial Results:
Compass Pathways Plc's operating loss for the second quarter of 2023 amounts to $-32.664 million,...

Compass Pathways Plc Faces Challenging First Quarter Results, Prompting Concerns Among Investors

The Major Pharmaceutical Preparations industry has been hit hard with disappointing news as Compass Pathways Plc announced its operating loss of $-31.788 million for the January to March 31 2023 interval. This is a major cause of concern for investors and shareholders who have been eagerly waiting for the company to return to profitability. Unfortunately, this doesn't seem to be happening anytime soon.
The company's revenue streams have not been evolving at the desired pace, and investors are not convinced about the current proficiency of the CMPS. The shareholders are looking forward to the company's management to come up with new financial plans to help cushion the losses and find new revenue sources. ...


Date modified: 2025-11-11T21:29:06+00:00




Help

About us

Terms of Use

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2025 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.